LL-37 Peptide – User Manual & Research Protocol Guide

LL-37 is a synthetic analog of a human antimicrobial peptide studied for its role in innate immune response, microbial defense, and tissue repair signaling. In research settings, it is explored for antimicrobial activity, inflammatory modulation, and wound-healing pathways.

Research Applications

Antimicrobial activity and host defense studies
Inflammatory response modulation models
Skin and tissue repair research
Biofilm interaction investigations
Immune signaling pathway analysis

Disclaimer: LL-37 is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried LL‑37 intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as an injectable research preparation after proper reconstitution.

LL-37 is studied for its ability to:

• Disrupt microbial membranes in experimental models
• Modulate cytokine and inflammatory signaling pathways
• Support wound-healing and tissue repair processes
• Influence immune cell recruitment and activation
• Interact with biofilm structures in laboratory settings

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 100–500 µg per administration, generally once daily, often in immune signaling studies.

Localized Research Model

Dosing is protocol-dependent with variable frequency, typically used for targeted tissue investigations.

Short-Course Research

Some studies use 100–300 µg daily for limited-duration protocols.

Important

There is no approved human dosage. The ranges above reflect commonly cited research patterns only.

Initiation

A 1-week phase used for initial response observation at the start of the study.

Active Study Phase

Typically 2–6 weeks, focused on evaluating immune function and tissue repair pathways.

Rest Period

A 2–4 week interval between study cycles to allow recovery and system reset.

Note

Cycle duration may vary depending on study design and research endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 5 mg vial + 2 mL → 2.5 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile handling techniqueRotate administration sites in injectable modelsDocument preparation concentration and dateFollow institutional research standards

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

Research use only
Not for therapeutic application
Human safety outside controlled research is not established
Potential research observations: injection-site irritation
Maintain sterile technique
Keep out of reach of unauthorized personnel

Peptide: LL-37
Category: Immune & Antimicrobial Research
Delivery: Injectable or localized research model
Typical Investigational Range: 100–500 µg per administration
Cycle: 2–6 week research protocols
Storage: Refrigerated after reconstitution